- Home
- EDIT vs SRG Comparison
EDIT vs SRG Comparison
Compare EDIT & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- SRG
- Stock Information
- Founded
- EDIT 2013
- SRG 2014
- Country
- EDIT United States
- SRG United States
- Employees
- EDIT N/A
- SRG N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- SRG Real Estate Investment Trusts
- Sector
- EDIT Health Care
- SRG Real Estate
- Exchange
- EDIT Nasdaq
- SRG Nasdaq
- Market Cap
- EDIT 269.8M
- SRG 236.0M
- IPO Year
- EDIT 2016
- SRG 2015
- Fundamental
- Price
- EDIT $2.75
- SRG $4.05
- Analyst Decision
- EDIT Buy
- SRG
- Analyst Count
- EDIT 11
- SRG 0
- Target Price
- EDIT $4.56
- SRG N/A
- AVG Volume (30 Days)
- EDIT 3.0M
- SRG 107.2K
- Earning Date
- EDIT 10-31-2025
- SRG 11-14-2025
- Dividend Yield
- EDIT N/A
- SRG N/A
- EPS Growth
- EDIT N/A
- SRG N/A
- EPS
- EDIT N/A
- SRG N/A
- Revenue
- EDIT $38,901,000.00
- SRG $15,346,000.00
- Revenue This Year
- EDIT N/A
- SRG N/A
- Revenue Next Year
- EDIT N/A
- SRG N/A
- P/E Ratio
- EDIT N/A
- SRG N/A
- Revenue Growth
- EDIT N/A
- SRG N/A
- 52 Week Low
- EDIT $0.91
- SRG $2.43
- 52 Week High
- EDIT $4.54
- SRG $4.72
- Technical
- Relative Strength Index (RSI)
- EDIT 35.84
- SRG 47.87
- Support Level
- EDIT $2.94
- SRG $4.00
- Resistance Level
- EDIT $3.37
- SRG $4.38
- Average True Range (ATR)
- EDIT 0.27
- SRG 0.13
- MACD
- EDIT -0.13
- SRG -0.02
- Stochastic Oscillator
- EDIT 1.60
- SRG 23.35
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.